[sheet: Timeline]
Event No. | Date | Event Category | Event Description | Key Parties / Personnel | Reference Document / IDR No. | Notes / Details
1 | 2022-05-16 | Examination | IRS issues initial contact letter (Letter 2205-A) opening examination of PPC for TY 2017–2020; Exam Team LB&I-NE-TP-2022-00641 | Gerald Meskill (IRS Team Manager), Patricia Dunleavy (Lead Revenue Agent) | Letter 2205-A | Examination covers transfer pricing methodology for Irish IP-holding structure; PPC EIN 22-3741856
2 | 2022-05-18 | Engagement | Leonard Cross emails Marcus Whitfield discussing receipt of IRS Letter 2205-A and recommending engagement of outside counsel | Leonard Cross (C&H), Marcus Whitfield (PPC VP Global Tax) | email-cross-to-whitfield-irs-letter-2205a-20220518.eml
3 | 2022-05-20 | Engagement | C&H conflicts check memorandum completed — engagement cleared against all parties including PPC, PBI, PHL, PMI, Crestfield & Associates, and relevant IRS personnel | Calderwood & Harkness LLP | conflict-check-memo.docx
4 | 2022-05-27 | Engagement | Draft engagement letter circulated to Marcus Whitfield and Deborah Staines for review | Leonard Cross, Marcus Whitfield, Deborah Staines (PPC General Counsel) | engagement-letter-ppc-draft.docx | Proposed scope, fee estimates ($4.5M–$7.0M), staffing plan
5 | 2022-06-02 | Engagement | Engagement letter executed between Calderwood & Harkness LLP and Penterra Pharmaceuticals Corp. for IRS examination defense (TY 2017–2020) | Leonard Cross (Responsible Partner), Sylvia Hartwell (Billing Partner), Marcus Whitfield | engagement-letter-ppc-executed.docx | Hourly rates: Cross $1,475, Hartwell $1,350, Simmons $885, Nazari $695; estimated fee range $4.5M–$7.0M; Matter No. 1018-00009
6 | 2022-06-03 | Engagement | Engagement kickoff email from Cross to Whitfield outlining immediate next steps: Form 2848 filing, initial document collection, coordination with Crestfield & Associates LLP | Leonard Cross, Marcus Whitfield | email-cross-to-whitfield-engagement-kickoff-20220603.eml
7 | 2022-06-06 | Engagement | Document preservation notice issued by C&H to PPC, PBI, PHL, and PMI directing preservation of all documents relevant to IRS examination of TY 2017–2020 | Calderwood & Harkness LLP | document-preservation-notice.docx | Litigation hold covers all entities in PPC group
8 | 2022-06-08 | Engagement | IRS Form 2848 (Power of Attorney) filed with IRS authorizing Leonard Cross, Sylvia Hartwell, Garrett Simmons, and Leila Nazari to represent PPC (EIN 22-3741856) for TY 2017–2020 | Cross, Hartwell, Simmons, Nazari | form-2848-power-of-attorney.docx
9 | 2022-06-10 | Engagement | Privilege protocol memorandum established for maintaining attorney-client privilege and work-product protection, including Kovel arrangement with Whitmore Valuation Group LLC | Leonard Cross | privilege-protocol-memo.docx
10 | 2022-06-15 | Analysis | Preliminary assessment memorandum delivered to PPC: initial assessment of IRS examination scope, PPC's transfer pricing positions (CSA cost-sharing ratios, 4.5% royalty rate, PCT valuation at $312M), potential exposure, and recommended defense strategy | Cross, Simmons, Whitfield, Staines | initial-assessment-memo.docx | CSA effective July 1, 2012; PCT payment $312M; legacy royalty 4.5% of non-Americas net sales
11 | 2022-06-20 | Engagement | Kovel engagement letter executed retaining Whitmore Valuation Group LLC under attorney-client privilege to provide economic analysis; reference 1018-00009-KV; Dr. Helena Vasquez designated as lead economist; blended rate $650/hr | Leonard Cross, Dr. Helena Vasquez (WVG Managing Director) | kovel-letter-whitmore-executed.docx
12 | 2022-06-21 | Engagement | Cross emails Dr. Vasquez outlining scope of Whitmore's economic analysis work and initial data requirements | Cross, Dr. Vasquez | email-cross-to-vasquez-whitmore-kickoff-20220621.eml
13 | 2022-06-22 | Correspondence | Letter from Cross to Supervisory Revenue Agent Gerald Meskill confirming IRS opening conference, identifying C&H as authorized representatives per Form 2848 | Cross, Meskill | letter-to-irs-opening-conference-20220622.docx
14 | 2022-06-28 | Examination | IRS opening conference held; C&H and PPC attend (Cross, Simmons, Whitfield); IRS team (Meskill, Dunleavy) outline examination scope, anticipated IDR schedule, and stated focus areas | Cross, Simmons, Whitfield, Meskill, Dunleavy | opening-conference-notes.docx | IRS focus areas: CSA cost-sharing ratios, royalty rate, PBI economic substance
15 | 2022-07-08 | IDR | Response to IDR No. 1 — Corporate structure and organizational charts (PPC, PHL, PBI, PMI ownership diagrams) | C&H to Dunleavy | idr-01-response.docx | PPC → PHL (disregarded entity) → PBI → PMI
16 | 2022-07-10 | Correspondence | Simmons emails Susan Lam at Crestfield & Associates requesting contemporaneous transfer pricing documentation, workpapers, and return data for TY 2017–2020 | Simmons, Susan Lam (Crestfield TP Partner) | email-simmons-to-lam-crestfield-data-request-20220710.eml
17 | 2022-07-12 | Analysis | Defense strategy memorandum delivered to PPC — comprehensive three-phase defense plan (IDR response, NOPA/Protest, Appeals); key legal and economic arguments; coordination plan with Whitmore and Thornbury & Keogh | Cross, Hartwell, Whitfield, Staines, Iyer (PPC CFO) | defense-strategy-memo.docx
18 | 2022-07-15 | IDR | Response to IDR No. 2 — CSA agreement effective July 1, 2012 and all amendments produced | C&H to Dunleavy | idr-02-response.docx | CSA scope: PBI acquired rights to develop/exploit IP outside Americas in exchange for PCT and ongoing cost-sharing
19 | 2022-07-20 | Analysis | IRC § 482 arm's-length standard and best method rule research memorandum completed (Nazari and Simmons); analyzes Treas. Reg. § 1.482-1(d), applicable case law | Nazari, Simmons | irc-482-legal-analysis-memo.docx
20 | 2022-07-22 | IDR | Response to IDR No. 3 — Legacy IP license agreement (4.5% royalty rate for non-Americas) produced | C&H to Dunleavy | idr-03-response.docx | Pre-2012 vintage compounds not covered by CSA
21 | 2022-07-25 | Analysis | Analysis of CSA agreement key terms and compliance with Treas. Reg. § 1.482-7 completed (Simmons) | Simmons | csa-agreement-analysis-memo.docx | Controlled participant eligibility, intangible development activity, reasonably anticipated benefits methodology
22 | 2022-07-28 | Analysis | Analysis of legacy IP license agreement royalty rate and terms for compliance with Treas. Reg. § 1.482-4 completed (Nazari) | Nazari | legacy-ip-license-analysis-memo.docx
23 | 2022-07-29 | Analysis | PHL entity classification and structure memorandum completed (Nazari) — PHL treated as disregarded entity for U.S. federal tax purposes | Nazari | phl-structure-memo.docx | PHL: Luxembourg S.à r.l.; RCS No. B 168452; 100% owner of PBI, itself 100% owned by PPC
24 | 2022-08-01 | IDR | Response to IDR No. 4 — Crestfield-prepared contemporaneous transfer pricing documentation for TY 2017–2020 produced | C&H to Dunleavy | idr-04-response.docx | Documentation prepared under IRC § 6662(e) penalty-protection standards
25 | 2022-08-05 | Analysis | Qualified cost-sharing arrangements regulatory analysis memorandum completed (Nazari); Treas. Reg. § 1.482-7 requirements, PCT payment methodologies, RAB shares | Nazari | csa-regulatory-analysis-memo.docx
26 | 2022-08-10 | IDR | Response to IDR No. 5 — Original PCT valuation report and supporting workpapers ($312M payment) produced | C&H to Dunleavy | idr-05-response.docx | PCT payment: $312M lump sum paid by PBI to PPC on July 1, 2012
27 | 2022-08-12 | Analysis | Arm's-length royalty rate analysis memorandum completed (Simmons); CUT method requirements, comparability factors for pharmaceutical IP licenses | Simmons | royalty-rate-analysis-memo.docx
28 | 2022-08-12 | Correspondence | Nazari emails Ciarán Thornbury at Thornbury & Keogh coordinating on Irish tax aspects; requests PBI's Irish Revenue filings and Knowledge Development box documentation | Nazari, Ciarán Thornbury (T&K Lead Partner) | email-nazari-to-thornbury-irish-coordination-20220812.eml | PBI Irish Tax Ref: 3218764T; KDB rate 6.25%; Irish standard trading rate 12.5%
29 | 2022-08-15 | Correspondence | Monthly status update from Cross to Whitfield on IDR response progress, upcoming deadlines, and coordination with Crestfield & Associates | Cross, Whitfield | email-cross-to-whitfield-status-update-20220815.eml
30 | 2022-08-18 | IDR | Response to IDR No. 6 — R&D cost pool composition and allocation methodology produced (2017: $487.3M; 2018: $523.8M; 2019: $561.2M; 2020: $598.4M) | C&H to Dunleavy | idr-06-response.docx | PBI cost-sharing percentages: 38.2%, 39.6%, 41.1%, 42.7%
31 | 2022-08-18 | Analysis | Economic substance doctrine and DEMPE functions research memorandum completed (Nazari); OECD Guidelines framework, relevant case law | Nazari | economic-substance-analysis-memo.docx
32 | 2022-08-25 | IDR | Response to IDR No. 7 — PBI Irish statutory financial statements and Irish tax returns for TY 2017–2020 produced | C&H to Dunleavy | idr-07-response.docx | PBI FY 2020 revenue: €2.14B; pre-tax income: €1.06B
33 | 2022-08-25 | Analysis | TCJA impact analysis memorandum completed (Nazari); effect of rate change from 35% to 21%, GILTI/BEAT implications for TY 2017 vs. 2018–2020 | Nazari | tcja-impact-analysis-memo.docx | U.S. rate: 35% (TY 2017 pre-TCJA); 21% (TY 2018–2020); TCJA effective Jan. 1, 2018
34 | 2022-08-25 | Engagement | Internal team email from Simmons coordinating IDR response assignments, deadlines, and document collection | Simmons, team | email-simmons-internal-idr-coordination-20220825.eml
35 | 2022-08-29 | Analysis | PMI contract manufacturing agreement analysis completed (Nazari); PBI-PMI cost + 8% arrangement assessed for arm's-length compliance | Nazari | pmi-manufacturing-agreement-analysis.docx | PMI: 620 employees, Ringaskiddy, Co. Cork; CRO No. 512347
36 | 2022-08-30 | Analysis | IRS IDR enforcement procedures research memorandum completed (Nazari); summons escalation, strategies for managing overbroad IDRs | Nazari | research-memo-idr-enforcement-procedures.docx
37 | 2022-09-02 | Analysis | IRC § 6662(e) penalty protection and reasonable cause defense memorandum completed (Simmons); contemporaneous documentation requirements | Simmons | penalty-protection-analysis-memo.docx | Proposed penalty: 20% of tax on § 482 allocation
38 | 2022-09-05 | IDR | Response to IDR No. 8 — PBI headcount data (52 in 2012 → 185 in 2020), org charts, key personnel role descriptions including Managing Director Aidan Naughton produced | C&H to Dunleavy | idr-08-response.docx
39 | 2022-09-12 | IDR | Response to IDR No. 9 — PBI board minutes for 42 meetings (2017–2020), articles of association, and governance documents produced | C&H to Dunleavy | idr-09-response.docx | All board meetings held in Dublin
40 | 2022-09-15 | Analysis | Case law analysis completed (Simmons and Nazari) — Altera Corp. v. Commissioner and Harborview Corporation, Inc. v. Commissioner; applicability to PPC's CSA and CUT positions | Simmons, Nazari | altera-Harborview Corporation-case-analysis.docx
41 | 2022-09-20 | IDR | Response to IDR No. 10 — PBI-PMI contract manufacturing agreement (cost + 8%) produced | C&H to Dunleavy | idr-10-response.docx
42 | 2022-09-20 | Correspondence | Letter from Cross to Dunleavy requesting 30-day extension to respond to IDR No. 14 (intercompany service fees) | Cross, Dunleavy | letter-to-irs-idr-extension-request-20220920.docx
43 | 2022-09-20 | Correspondence | Letter from Cross to Martin Ogilvy at Crestfield & Associates providing C&H's legal analysis in support of PPC's FIN 48 reserve for transfer pricing positions | Cross, Martin Ogilvy (Crestfield Engagement Partner) | letter-to-crestfield-fin48-support-20220920.docx | PPC FIN 48 reserve: $62.4M (ASC 740-10)
44 | 2022-09-22 | Analysis | FIN 48 / ASC 740-10 reserve analysis memorandum completed (Cross and Simmons); legal analysis supporting PPC's $62.4M uncertain tax position reserve related to Irish IP structure | Cross, Simmons | fin-48-reserve-analysis-memo.docx | Reserve covers CSA, royalty, and PCT positions
45 | 2022-09-25 | Analysis | PBI board minutes analysis memorandum completed (Nazari); 42 meetings catalogued covering pricing, market entry, regulatory submissions, capital expenditures — all held in Dublin | Nazari | pbi-board-minutes-analysis.docx
46 | 2022-09-26 | Analysis | PBI personnel interview summaries completed — 12 key employees interviewed in Dublin (August–September 2022); roles, decision-making authority, functional contributions documented | Simmons, Nazari | pbi-personnel-interview-summaries.docx
47 | 2022-09-28 | Analysis | IRC § 367(d) outbound IP transfer considerations memorandum completed (Nazari); potential IRS recharacterization of CSA as § 367(d) transfer | Nazari | irc-367d-analysis-memo.docx
48 | 2022-10-01 | Engagement | Q3 2022 matter status report delivered to PPC management | Cross, Hartwell | matter-status-report-q3-2022.docx
49 | 2022-10-03 | IDR | Response to IDR No. 11 — Product-level revenue data by territory for Veritaxol, Imvara, and Cerulon (2017–2020) produced | C&H to Dunleavy | idr-11-response.docx | 2020 non-Americas: Veritaxol $1.34B, Imvara $0.79B, Cerulon $0.28B
50 | 2022-10-05 | Engagement | Internal strategy discussion email: Cross to Hartwell on IRS exam team's apparent focus on royalty rate and PBI substance | Cross, Hartwell | email-cross-to-hartwell-strategy-discussion-20221005.eml
51 | 2022-10-10 | Analysis | OECD Transfer Pricing Guidelines (2017 & 2022) as persuasive authority memorandum completed (Simmons); Chapter VI (intangibles), Chapter VIII (CSAs) | Simmons | oecd-guidelines-analysis-memo.docx
52 | 2022-10-12 | IDR | Response to IDR No. 12 — PBI office lease (~18,000 sq ft at Sandyford Business Park, Dublin) and physical presence documentation produced | C&H to Dunleavy | idr-12-response.docx
53 | 2022-10-18 | Analysis | Functional analysis report completed — PBI's functions, assets, and risks (2017–2020); regulatory, commercial-strategy, supply-chain, medical-affairs activities in Dublin; 185 employees, 42 board meetings, €47.2M regulatory spend, 68 country markets | C&H, Whitmore Valuation Group | functional-analysis-report.docx
54 | 2022-10-18 | Analysis | GILTI and BEAT impact analysis completed (Nazari); interaction between IRS proposed § 482 adjustments and PPC's GILTI/BEAT positions for TY 2018–2020 | Nazari | gilti-beat-impact-analysis.docx
55 | 2022-10-18 | Correspondence | Simmons follow-up email to Susan Lam at Crestfield requesting detailed R&D cost pool breakdowns for each year ($487.3M–$598.4M) | Simmons, Susan Lam | email-simmons-to-lam-crestfield-follow-up-20221018.eml
56 | 2022-10-28 | Engagement | Simmons assigns Nazari to research penalty protection standards under IRC § 6662(e) and contemporaneous documentation requirements | Simmons, Nazari | email-simmons-to-nazari-penalty-research-20221028.eml
57 | 2022-11-08 | IDR | Response to IDR No. 15 — PBI cumulative €47.2M regulatory expenditures and submissions across 68 country markets (2017–2020) produced | C&H to Dunleavy | idr-15-response.docx
58 | 2022-11-15 | Correspondence | Nazari emails Thornbury at T&K requesting additional PBI substance documentation: lease agreements, employee contracts, Glenmore Bank Ireland plc account records | Nazari, Thornbury | email-nazari-to-thornbury-irish-substance-docs-20221115.eml
59 | 2022-11-18 | Analysis | CUT analysis report completed by Whitmore Valuation Group — 14 comparable uncontrolled pharmaceutical license agreements identified; royalty IQR 3.1%–6.8%; median 4.4%; PPC's 4.5% within arm's-length range | Dr. Helena Vasquez, Dr. Rohan Chakrabarti (WVG) | cut-analysis-royalty-report.docx
60 | 2022-11-22 | Analysis | CPM / TNMM analysis report completed by Whitmore — 22 comparable distributors and IP-holding companies tested; PBI's operating margins within IQR in all four years | Dr. Vasquez, Dr. Chakrabarti | cpm-tnmm-analysis-report.docx
61 | 2022-12-05 | IDR | Response to IDR No. 18 — PBI distribution partner agreements for non-Americas territories produced, demonstrating independent commercial decision-making | C&H to Dunleavy | idr-18-response.docx
62 | 2022-12-12 | Analysis | PCT valuation analysis (income method / DCF) completed by Whitmore — WACC 9.8% (vs. IRS 7.2%); arm's-length range $278M–$361M; $312M PCT payment within range | Dr. Vasquez | pct-valuation-dcf-report.docx | IRS proposed PCT value: $852M; delta $540M
63 | 2022-12-15 | Analysis | WACC / Discount rate analysis technical memorandum completed by Dr. Vasquez supporting 9.8% WACC; criticizes IRS's 7.2% rate; risk premiums, beta comparables, pharma cost of capital | Dr. Vasquez | wacc-discount-rate-analysis.docx
64 | 2023-01-05 | Engagement | Q4 2022 matter status report delivered to PPC management | Cross, Hartwell | matter-status-report-q4-2022.docx
65 | 2023-01-20 | IDR | Response to IDR No. 22 — PBI bank statements with Glenmore Bank Ireland plc produced, demonstrating independent treasury operations | C&H to Dunleavy | idr-22-response.docx
66 | 2023-02-15 | IDR | Response to IDR No. 25 — Redacted third-party license agreements identified as comparables in PPC's CUT analysis produced | C&H to Dunleavy | idr-25-response.docx | 14 CUT comparable agreements
67 | 2023-02-15 | Correspondence | Letter from Cross to Dunleavy objecting to scope of IDR No. 26 as overly broad and unduly burdensome; requests narrowing | Cross, Dunleavy | letter-to-irs-idr-scope-objection-20230215.docx
68 | 2023-03-15 | Analysis | Updated functional analysis completed — incorporates additional PBI employee interviews and documentary evidence from 2022–2023 IDR process | C&H, Whitmore | functional-analysis-report-updated.docx
69 | 2023-03-15 | Correspondence | Mid-examination status update from Cross to Whitfield; discusses IRS economist Dr. Alan Washburne's involvement and anticipated NOPA timeline | Cross, Whitfield | email-cross-to-whitfield-status-update-20230315.eml
70 | 2023-04-03 | Engagement | Q1 2023 matter status report delivered | Cross, Hartwell | matter-status-report-q1-2023.docx
71 | 2023-04-05 | Engagement | Internal budget update: Hartwell to Cross reviewing fee expenditure to date against $4.5M–$7.0M estimate with projected costs through Appeals | Hartwell, Cross | email-hartwell-to-cross-budget-update-20230405.eml
72 | 2023-04-10 | IDR | Response to IDR No. 30 — PBI Knowledge Development box claims (6.25% rate) and Irish Revenue filings produced | C&H to Dunleavy | idr-30-response.docx | KDB effective FY 2016+
73 | 2023-05-10 | Correspondence | Letter from Cross to Meskill requesting mid-examination conference to discuss status and narrow remaining issues | Cross, Meskill | letter-to-irs-mid-exam-conference-20230510.docx
74 | 2023-05-25 | Examination | Mid-examination conference held; IRS's preliminary positions discussed; remaining IDRs reviewed; anticipated NOPA timeline communicated | Cross, Simmons, Whitfield, Meskill, Dunleavy | mid-exam-conference-notes.docx
75 | 2023-06-02 | IDR | Response to IDR No. 35 — Internal PBI documents evidencing independent pricing decisions across 68 non-Americas markets produced | C&H to Dunleavy | idr-35-response.docx
76 | 2023-07-05 | Engagement | Q2 2023 matter status report delivered | Cross, Hartwell | matter-status-report-q2-2023.docx
77 | 2023-07-18 | IDR | Response to IDR No. 40 — Forms 5471 for PBI and PHL for TY 2017–2020 produced | C&H to Dunleavy | idr-40-response.docx
78 | 2023-07-20 | Correspondence | Status update from Cross discussing intelligence on IRS economist's analysis direction, potential adjustment amounts, and strategic positioning | Cross, Whitfield | email-cross-to-whitfield-status-update-20230720.eml
79 | 2023-08-15 | Examination | Meeting/call with IRS economist Dr. Alan Washburne; discussion of his economic methodology, comparable selection, and discount rate assumptions | Cross, Simmons, Dr. Washburne | irs-economist-meeting-notes.docx | IRS using 7.2% WACC; IRS CUT analysis supports 11.0% royalty rate
80 | 2023-08-22 | IDR | Response to IDR No. 44 — PBI capital expenditure records, equipment purchases, and IT infrastructure investments for 2017–2020 produced | C&H to Dunleavy | idr-44-response.docx
81 | 2023-09-20 | Examination | Call with IRS Chief Counsel Attorney-Advisor Franklin Rosario; legal positions on CSA compliance and economic substance discussed | Cross, Simmons, Franklin Rosario | irs-chief-counsel-meeting-notes.docx | Senior Counsel Donna Hirabayashi also supporting IRS position
82 | 2023-09-29 | IDR | Response to IDR No. 47 (final IDR) — Supplemental documentation including additional employee compensation data and travel records produced | C&H to Dunleavy | idr-47-response.docx | 47 total IDRs issued between June 2022 and September 2023
83 | 2023-10-03 | Engagement | Q3 2023 matter status report delivered; covers NOPA issuance | Cross, Hartwell | matter-status-report-q3-2023.docx
84 | 2023-10-12 | NOPA-Protest | NOPA (Notice of Proposed Adjustment) issued by IRS for all four tax years; total proposed adjustment $380.4M (CSA: $235.01M; royalty: $188.04M; correlative offset: -$42.65M) | IRS (Meskill, Dunleavy, Dr. Washburne, Rosario) | proposed-adjustment-summary.xlsx | Proposed penalty: $15.98M (20% of tax on $380.4M at 21%)
85 | 2023-10-15 | NOPA-Protest | Cross emails Whitfield reporting receipt and initial assessment of NOPA; summarizes $380.4M proposed adjustments; recommends immediate conference call | Cross, Whitfield | email-cross-to-whitfield-nopa-received-20231015.eml
86 | 2023-10-15 | Engagement | Internal NOPA review assignments: Nazari to analyze legal positions; Simmons to coordinate with Whitmore on economic rebuttal; Cross/Hartwell to manage client communication | Simmons, Nazari, Cross, Hartwell | email-simmons-internal-nopa-review-assignment-20231015.eml
87 | 2023-10-20 | NOPA-Protest | Detailed NOPA analysis memorandum completed (Simmons and Nazari); breakdown of $380.4M (CSA adjustments by year: $48.73M/$57.61M/$62.85M/$65.82M; royalty adjustments: $52.95M/$49.55M/$44.97M/$40.57M); IRS legal and economic position vulnerabilities identified | Simmons, Nazari | nopa-analysis-memo.docx | IRS proposed CSA %: 48.2%/50.6%/52.3%/53.7% vs. PPC's 38.2%/39.6%/41.1%/42.7%; IRS royalty: 11.0% vs. PPC's 4.5%
88 | 2023-10-22 | Analysis | Correlative adjustments research memorandum completed (Nazari); Treas. Reg. § 1.482-1(g) analysis supporting $42.65M offset to avoid double-counting between CSA and royalty adjustments | Nazari | research-memo-correlative-adjustments.docx
89 | 2023-10-25 | Correspondence | Letter from Cross to Meskill and Dunleavy acknowledging NOPA receipt, reserving all rights, requesting extension for formal Protest | Cross, Meskill, Dunleavy | letter-to-irs-response-to-nopa-20231025.docx
90 | 2023-11-08 | NOPA-Protest | 30-Day Letter issued by IRS | IRS | 30-day-letter-analysis-memo.docx | Options: Protest to Appeals or petition Tax Court
91 | 2023-11-09 | NOPA-Protest | Cross emails Whitfield discussing 30-Day Letter, explaining options and recommending Protest filing with extension request | Cross, Whitfield | email-cross-to-whitfield-30-day-letter-20231109.eml
92 | 2023-11-10 | Analysis | 30-Day Letter analysis memorandum completed (Nazari); procedural options, deadlines, strategic considerations | Nazari | 30-day-letter-analysis-memo.docx
93 | 2023-11-15 | Correspondence | Letter from Cross to Meskill requesting extension of Protest deadline from November 8 to December 22, 2023 | Cross, Meskill | letter-to-irs-protest-extension-20231115.docx | Extension granted by agreement
94 | 2023-11-20 | Correspondence | Updated FIN 48 letter to Crestfield — revised legal conclusions following NOPA for PPC's year-end 2023 financial statement reserve analysis | Cross, Martin Ogilvy | letter-to-crestfield-fin48-update-20231120.docx
95 | 2023-11-22 | Analysis | Updated FIN 48 analysis post-NOPA: reassessment of $62.4M reserve in light of $380.4M proposed adjustments and litigation hazards | Cross, Simmons | fin-48-reserve-update-post-nopa.docx
96 | 2023-11-25 | Analysis | Hargrove credit facility tax covenant analysis completed (Nazari); assesses whether $380.4M proposed adjustment triggers reporting or default provisions under PPC's $1.5B revolving credit facility with Hargrove National Bank, N.A. | Nazari | hargrove-covenant-analysis-memo.docx | Admin agent: Christine Bellucci, SVP
97 | 2023-11-25 | Analysis | SEC disclosure considerations memorandum completed (Simmons); PPC's 10-K/10-Q obligations regarding IRS examination, contingent liabilities, FIN 48 reserves; notes Ridgeview Capital Management LP (8.3% shareholder, Managing Partner Douglas Everett) monitoring | Simmons | sec-disclosure-analysis-memo.docx
98 | 2023-11-25 | Correspondence | Cross emails PPC General Counsel Deborah Staines regarding SEC disclosure considerations for upcoming 10-K filing in light of $380.4M proposed adjustment | Cross, Staines | email-cross-to-staines-sec-disclosure-20231125.eml
99 | 2023-12-01 | Appeals | Appeals strategy memorandum delivered to PPC; outlines settlement posture, hazards-of-litigation analysis, recommended opening and target positions, conference preparation | Cross, Hartwell, Whitfield, Staines | appeals-strategy-memo.docx
100 | 2023-12-05 | Appeals | Hazards of litigation analysis completed (Cross to Hartwell); privileged analysis of litigation hazards on each IRS position; probability-weighted Tax Court outcome ranges | Cross, Hartwell | hazards-of-litigation-memo.docx
101 | 2023-12-05 | NOPA-Protest | Draft Formal Protest — Version 1 circulated internally at C&H | Simmons, Nazari, Cross, Hartwell | formal-protest-draft-v1.docx
102 | 2023-12-10 | Appeals | Settlement authority memorandum delivered; recommends target resolution at 10–15% of proposed $380.4M adjustment, hard ceiling of 20% | Cross, Whitfield, Staines | settlement-authority-memo.docx | Target: $38.0M–$57.1M; ceiling: $76.1M
103 | 2023-12-12 | NOPA-Protest | Draft Formal Protest — Version 2 circulated incorporating Cross's and Hartwell's comments | Cross, Hartwell, Simmons | formal-protest-draft-v2.docx; formal-protest-redline-v1-to-v2.docx
104 | 2023-12-13 | Analysis | Competent authority relief analysis completed (Cross); U.S.-Ireland Income Tax Treaty MAP request potential; assessment of whether to pursue to avoid double taxation | Cross | competent-authority-analysis-memo.docx
105 | 2023-12-14 | Analysis | Rev. Proc. 2015-41 research memorandum completed (Nazari); IRS Appeals conference procedures | Nazari | research-memo-rev-proc-2015-41.docx
106 | 2023-12-16 | NOPA-Protest | Draft Formal Protest — Version 3 (near-final) sent to Marcus Whitfield and Deborah Staines for client review | Cross, Whitfield, Staines | formal-protest-draft-v3-client-review.docx; formal-protest-redline-v2-to-v3.docx
107 | 2023-12-16 | Correspondence | Cross emails Whitfield and Staines transmitting Version 3 of Protest for review; filing deadline December 22, 2023 | Cross, Whitfield, Staines | email-cross-to-whitfield-protest-draft-review-20231216.eml
108 | 2023-12-19 | NOPA-Protest | Whitfield provides PPC's comments on draft Protest; approves filing with minor revisions | Whitfield, Cross | email-whitfield-to-cross-protest-comments-20231219.eml
109 | 2023-12-22 | NOPA-Protest | Formal Protest filed with IRS on behalf of PPC contesting $380.4M proposed adjustments for TY 2017–2020; transfer pricing defense under IRC § 482, Treas. Reg. §§ 1.482-4, 1.482-7; defends CSA cost-sharing ratios, 4.5% royalty rate, $312M PCT valuation, PBI economic substance / DEMPE functions, contemporaneous documentation, penalty protection | Cross, Hartwell (C&H), Whitfield (PPC) | formal-protest-filed.docx; Exhibits A–E | Exhibits: A (entity chart), B (CSA summary), C (economic analyses), D (PBI substance), E (penalty protection)
110 | 2024-01-05 | Engagement | Q4 2023 matter status report delivered; covers Protest filing and Appeals transition | Cross, Hartwell | matter-status-report-q4-2023.docx
111 | 2024-01-08 | Appeals | Case assigned to Appeals Officer Noreen Castañeda | Noreen Castañeda (IRS Appeals)
112 | 2024-01-05 | Correspondence | Cross emails Dr. Vasquez requesting preparation of rebuttal memorandum addressing Dr. Washburne's economic analysis underpinning the NOPA for use in Appeals | Cross, Dr. Vasquez | email-cross-to-vasquez-whitmore-rebuttal-20240105.eml
113 | 2024-01-05 | Correspondence | Nazari emails Thornbury at T&K discussing potential mutual agreement procedure request under U.S.-Ireland treaty and Irish Revenue coordination | Nazari, Thornbury | email-nazari-to-thornbury-competent-authority-20240105.eml
114 | 2024-01-10 | Appeals | Letter from Cross to Appeals Officer Castañeda requesting scheduling of Appeals conference; proposes dates in late February 2024 | Cross, Castañeda | letter-to-irs-appeals-conference-request-20240110.docx
115 | 2024-01-22 | Analysis | Rebuttal of IRS economist's analysis completed by Dr. Vasquez and Dr. Chakrabarti (Whitmore); challenges Dr. Washburne's CUT selection criteria, discount rate assumptions, and projected revenue growth rates | Dr. Vasquez, Dr. Chakrabarti | irs-economist-rebuttal-memo.docx
116 | 2024-02-10 | Appeals | Simmons emails Dr. Vasquez providing updated financial data and requesting final slides for Appeals conference presentation | Simmons, Dr. Vasquez | email-simmons-to-vasquez-appeals-data-20240210.eml
117 | 2024-02-15 | Appeals | Appeals pre-conference memorandum completed; key arguments, anticipated Appeals Officer questions, witness preparation notes, conference logistics (Feb. 28, IRS Appeals Office, Manhattan) | Cross, C&H team, PPC | appeals-pre-conference-memo.docx
118 | 2024-02-15 | Appeals | Internal Appeals conference preparation email from Cross; outlines preparation tasks, presentation finalization, document binders, role assignments | Cross, team | email-cross-to-team-appeals-prep-20240215.eml
119 | 2024-02-20 | Appeals | Witness preparation memorandum for Marcus Whitfield completed; key facts, anticipated questions, messaging for Appeals conference | Cross | witness-preparation-memo-whitfield.docx
120 | 2024-02-22 | Appeals | Witness preparation memorandum for Dr. Helena Vasquez completed; preparation to present Whitmore's economic analyses at Appeals conference | Simmons | witness-preparation-memo-vasquez.docx
121 | 2024-02-28 | Appeals | Appeals conference held at IRS Appeals Office, Manhattan; attended by C&H (Cross, Hartwell, Simmons), PPC (Whitfield, Staines), Whitmore (Dr. Vasquez), IRS (Appeals Officer Castañeda) | Cross, Hartwell, Simmons, Whitfield, Staines, Dr. Vasquez, Castañeda | appeals-conference-presentation.pptx; appeals-conference-talking-points.docx; appeals-conference-attendee-list.docx; appeals-brief-document-binder-index.docx | Presentation covered: case overview, PPC positions, factual background, economic analyses, PBI substance, legal arguments, proposed resolution
122 | 2024-03-01 | Appeals | Post-conference summary memorandum completed (Simmons); documents Appeals Officer Castañeda's questions and reactions, areas of agreement/disagreement, next steps | Simmons | appeals-conference-summary.docx
123 | 2024-03-01 | Correspondence | Cross emails Whitfield, Staines, and Iyer debriefing Appeals conference; summarizes Castañeda's receptiveness and likely settlement trajectory | Cross, Whitfield, Staines, Iyer | email-cross-to-whitfield-appeals-conference-debrief-20240301.eml
124 | 2024-03-08 | Appeals | Supplemental written submission from Cross to Appeals Officer Castañeda providing additional comparable license agreements and updated benchmarking data requested during conference | Cross, Castañeda | appeals-supplemental-submission.docx
125 | 2024-03-15 | Settlement | Appeals Officer Castañeda issues settlement offer: $47.6M total adjustment across all four years (12.51% of $380.4M proposed); allocation: TY 2017 $11.2M / TY 2018 $12.4M / TY 2019 $12.8M / TY 2020 $11.2M; full penalty abatement | Castañeda | Tax due: $47.6M × 21% = $10.0M; estimated interest: ~$2.84M; penalty: $0
126 | 2024-03-18 | Settlement | Settlement offer analysis memorandum completed (Cross and Hartwell to Whitfield, Staines, Iyer); recommends acceptance; total cash cost to PPC ~$12.84M (tax $10.0M + interest $2.84M); FIN 48 reserve impact: reduction from $62.4M to $14.8M | Cross, Hartwell, Whitfield, Staines, Iyer | settlement-offer-analysis-memo.docx; settlement-financial-impact-analysis.xlsx | Savings vs. full proposed: $83.02M (86.6% reduction)
127 | 2024-03-18 | Correspondence | Cross emails Whitfield and Staines transmitting settlement offer analysis memo and recommending acceptance | Cross, Whitfield, Staines | email-cross-to-whitfield-settlement-offer-20240318.eml
128 | 2024-03-19 | Correspondence | Cross emails CFO Rajesh Iyer summarizing total financial impact: tax $10.0M, interest ~$2.84M, $0 penalty, total cash cost ~$12.84M, FIN 48 reserve impact | Cross, Iyer | email-cross-to-iyer-financial-impact-20240319.eml
129 | 2024-03-20 | Correspondence | Nazari emails Thornbury at T&K analyzing potential Irish tax consequences of $47.6M U.S. settlement, including impact on PBI's Knowledge Development box claims | Nazari, Thornbury | email-nazari-to-thornbury-settlement-irish-impact-20240320.eml
130 | 2024-03-21 | Settlement | PPC management (Iyer, CEO Catherine Falk) approves acceptance of $47.6M settlement; Whitfield confirms to Cross | Whitfield, Cross, Iyer, Falk | email-whitfield-to-cross-settlement-approved-20240321.eml
131 | 2024-03-22 | Settlement | PPC accepts settlement; letter from Cross to Appeals Officer Castañeda accepting $47.6M total adjustment with allocation across TY 2017–2020 ($11.2M/$12.4M/$12.8M/$11.2M) and full penalty abatement | Cross, Castañeda | letter-to-irs-appeals-settlement-acceptance-20240322.docx
132 | 2024-03-29 | Settlement | IRS Form 906 Closing Agreement executed (signed by PPC — Marcus Whitfield — and IRS Appeals); memorializes $47.6M settlement; examination formally closed | Whitfield (PPC), IRS Appeals | form-906-closing-agreement-executed.docx | Total cost to PPC: ~$21.17M (professional fees ~$8.33M + tax $10.0M + interest $2.84M)
133 | 2024-03-29 | Settlement | Cross emails Whitfield confirming execution of Form 906 Closing Agreement and formal closure of IRS examination | Cross, Whitfield | email-cross-to-whitfield-closing-agreement-executed-20240329.eml
134 | 2024-03-29 | Engagement | Matter closing memorandum completed; Matter 1018-00009 closed; outcomes: $47.6M settlement (12.51% of proposed $380.4M), penalty fully abated, total cost ~$21.17M, total C&H fees $5,837,420 | Cross | matter-closing-memo.docx | WVG fees: $2,146,800; T&K fees: €312,500 (~$341,200)
135 | 2024-03-30 | Analysis | Updated FIN 48 analysis post-settlement; reserve reduced from $62.4M to $14.8M; basis for remaining reserve documented | Cross, Simmons | fin-48-reserve-update-post-settlement.docx
136 | 2024-04-01 | Post-Settlement | Letter from Cross and Hartwell to Whitfield summarizing examination resolution, settlement terms, and next steps (amended returns, interest payment) | Cross, Hartwell, Whitfield | letter-to-whitfield-closing-summary-20240401.docx
137 | 2024-04-02 | Engagement | Final Q1 2024 matter status report delivered; summarizes Appeals resolution, settlement execution, matter closure on March 29, 2024 | Cross, Hartwell | matter-status-report-q1-2024.docx
138 | 2024-04-05 | Post-Settlement | Amended return filing instructions memorandum delivered (Simmons to Whitfield); instructions for Forms 1120X for TY 2017–2020 reflecting $47.6M settlement adjustment | Simmons, Whitfield | amended-return-instructions-memo.docx
139 | 2024-04-10 | Post-Settlement | State tax impact analysis memorandum completed (Nazari); potential state income tax consequences of federal $47.6M adjustment in NJ and other filing states, apportionment effects | Nazari | state-tax-impact-analysis-memo.docx
140 | 2024-04-15 | Post-Settlement | Going-forward transfer pricing recommendations memorandum delivered; recommends adjustments to PPC's TP documentation, cost-sharing calculations, and PBI substance for TY 2021+ | Cross, Hartwell, Whitfield | going-forward-recommendations-memo.docx
141 | 2024-04-15 | Correspondence | Cross emails Whitfield transmitting going-forward recommendations memo; offers to schedule call with PPC management to discuss implementation | Cross, Whitfield | email-cross-to-whitfield-going-forward-recs-20240415.eml
142 | 2024-04-20 | Post-Settlement | Advance Pricing Agreement (APA) considerations memorandum delivered (Cross); analyzes pros/cons of bilateral APA with IRS and Irish Revenue for future tax years | Cross | apa-consideration-memo.docx
143 | 2024-04-22 | Post-Settlement | PBI substance enhancement recommendations memorandum delivered (Simmons to Whitfield); additional headcount, expanded board governance, documentation of DEMPE functions | Simmons, Whitfield | pbi-substance-enhancement-recommendations.docx
144 | 2024-04-22 | Correspondence | Cross emails Whitfield transmitting APA consideration memo and suggesting next steps | Cross, Whitfield | email-cross-to-whitfield-apa-discussion-20240422.eml
[sheet: IDR Log Summary]
IDR No. | Date Issued | Subject / Description | Due Date | Response Date | Status | Timeline Event No. | Response Document Reference
1 | 2022-06-28 | Corporate structure and organizational charts | 2022-07-12 | 2022-07-08 | Responded | 15 | idr-01-response.docx
2 | 2022-07-05 | Cost-Sharing Arrangement agreement and amendments | 2022-07-19 | 2022-07-15 | Responded | 18 | idr-02-response.docx
3 | 2022-07-12 | Legacy IP license agreement (4.5% royalty) | 2022-07-26 | 2022-07-22 | Responded | 20 | idr-03-response.docx
4 | 2022-07-18 | Transfer pricing documentation (TY 2017–2020) | 2022-08-04 | 2022-08-01 | Responded | 24 | idr-04-response.docx
5 | 2022-07-25 | PCT valuation and supporting workpapers ($312M) | 2022-08-15 | 2022-08-10 | Responded | 26 | idr-05-response.docx
6 | 2022-08-01 | R&D cost pool and allocation methodology | 2022-08-22 | 2022-08-18 | Responded | 30 | idr-06-response.docx
7 | 2022-08-08 | PBI financial statements and Irish tax returns (TY 2017–2020) | 2022-08-29 | 2022-08-25 | Responded | 32 | idr-07-response.docx
8 | 2022-08-15 | PBI personnel and headcount data (52→185) | 2022-09-08 | 2022-09-05 | Responded | 38 | idr-08-response.docx
9 | 2022-08-22 | PBI board minutes and governance documents (42 meetings) | 2022-09-15 | 2022-09-12 | Responded | 39 | idr-09-response.docx
10 | 2022-08-29 | PMI contract manufacturing agreement (cost + 8%) | 2022-09-22 | 2022-09-20 | Responded | 41 | idr-10-response.docx
11 | 2022-09-12 | Product revenue data by territory (Veritaxol, Imvara, Cerulon) | 2022-10-06 | 2022-10-03 | Responded | 49 | idr-11-response.docx
12 | 2022-09-22 | PBI office lease and physical presence (~18,000 sq ft Sandyford) | 2022-10-14 | 2022-10-12 | Responded | 52 | idr-12-response.docx
13 | 2022-09-01 | Intercompany pricing benchmarking studies | 2022-09-22 | 2022-09-19 | Responded | idr-13-response.docx
14 | 2022-09-08 | Intercompany service fees | 2022-10-01 | 2022-10-31 | Extension Granted (30 days) | 42 | idr-14-response.docx
15 | 2022-10-18 | Regulatory expenditures and submissions (€47.2M, 68 markets) | 2022-11-10 | 2022-11-08 | Responded | 57 | idr-15-response.docx
16 | 2022-10-25 | PPC consolidated financial statements (TY 2017–2020) | 2022-11-18 | 2022-11-15 | Responded | idr-16-response.docx
17 | 2022-11-01 | Intercompany loan and financing arrangements | 2022-11-22 | 2022-11-20 | Responded | idr-17-response.docx
18 | 2022-11-14 | Third-party distribution agreements (non-Americas) | 2022-12-08 | 2022-12-05 | Responded | 61 | idr-18-response.docx
19 | 2022-11-28 | PBI marketing and promotional expenditures (2017–2020) | 2022-12-19 | 2022-12-16 | Responded | idr-19-response.docx
20 | 2022-12-05 | PPC R&D project descriptions and milestone reports | 2022-12-28 | 2022-12-22 | Responded | idr-20-response.docx
21 | 2022-12-12 | PBI intellectual property registrations and patent filings | 2023-01-05 | 2023-01-03 | Responded | idr-21-response.docx
22 | 2023-01-04 | PBI banking records — Glenmore Bank Ireland plc statements | 2023-01-25 | 2023-01-20 | Responded | 65 | idr-22-response.docx
23 | 2023-01-09 | PBI employee travel records and expense reports (2017–2020) | 2023-01-30 | 2023-01-27 | Responded | idr-23-response.docx
24 | 2023-01-16 | PPC segment reporting and management accounts | 2023-02-06 | 2023-02-03 | Responded | idr-24-response.docx
25 | 2023-01-25 | Comparable license agreements (CUT support, 14 agreements) | 2023-02-18 | 2023-02-15 | Responded | 66 | idr-25-response.docx
26 | 2023-01-30 | Broad financial data request (scope objected to) | 2023-02-20 | 2023-03-01 | Objection Filed; scope narrowed | 67 | idr-26-response.docx
27 | 2023-02-06 | PBI insurance policies and risk management documentation | 2023-02-27 | 2023-02-24 | Responded | idr-27-response.docx
28 | 2023-02-13 | PPC transfer pricing policy manuals | 2023-03-06 | 2023-03-03 | Responded | idr-28-response.docx
29 | 2023-02-27 | PBI clinical trial expenditure data by product (2017–2020) | 2023-03-20 | 2023-03-17 | Responded | idr-29-response.docx
30 | 2023-03-20 | Knowledge Development box claims and Irish Revenue filings (6.25% rate) | 2023-04-14 | 2023-04-10 | Responded | 72 | idr-30-response.docx
31 | 2023-03-27 | PBI supply chain and logistics documentation | 2023-04-17 | 2023-04-14 | Responded | idr-31-response.docx
32 | 2023-04-03 | PPC APA history and prior IRS examination records | 2023-04-24 | 2023-04-21 | Responded | idr-32-response.docx
33 | 2023-04-10 | PBI medical affairs team reports and submissions | 2023-05-01 | 2023-04-28 | Responded | idr-33-response.docx
34 | 2023-04-24 | PBI third-party consultant and CRO agreements | 2023-05-15 | 2023-05-12 | Responded | idr-34-response.docx
35 | 2023-05-15 | Intercompany pricing decisions and market strategy (68 markets) | 2023-06-08 | 2023-06-02 | Responded | 75 | idr-35-response.docx
36 | 2023-05-22 | PBI quality assurance and GMP compliance records | 2023-06-12 | 2023-06-09 | Responded | idr-36-response.docx
37 | 2023-06-05 | PPC internal audit reports related to transfer pricing | 2023-06-26 | 2023-06-23 | Responded | idr-37-response.docx
38 | 2023-06-12 | PBI employee compensation and bonus structure data | 2023-07-03 | 2023-06-30 | Responded | idr-38-response.docx
39 | 2023-06-19 | PMI operational data and cost accounting records | 2023-07-10 | 2023-07-07 | Responded | idr-39-response.docx
40 | 2023-06-26 | Forms 5471 for PBI and PHL (TY 2017–2020) | 2023-07-21 | 2023-07-18 | Responded | 77 | idr-40-response.docx
41 | 2023-07-10 | PBI IT systems and data infrastructure documentation | 2023-07-31 | 2023-07-28 | Responded | idr-41-response.docx
42 | 2023-07-17 | PPC board presentations referencing international operations | 2023-08-07 | 2023-08-04 | Responded | idr-42-response.docx
43 | 2023-07-24 | PBI vendor and supplier contracts (non-manufacturing) | 2023-08-14 | 2023-08-11 | Responded | idr-43-response.docx
44 | 2023-08-02 | PBI capital expenditure and investment records | 2023-08-25 | 2023-08-22 | Responded | 80 | idr-44-response.docx
45 | 2023-08-14 | PBI regulatory submission timeline and approval records | 2023-09-05 | 2023-09-01 | Responded | idr-45-response.docx
46 | 2023-08-28 | PBI strategic planning documents and market analyses | 2023-09-18 | 2023-09-15 | Responded | idr-46-response.docx
47 | 2023-09-11 | Supplemental documentation — employee compensation and travel records (final IDR) | 2023-10-02 | 2023-09-29 | Responded | 82 | idr-47-response.docx
[sheet: Key Milestones Summary]
Milestone | Date | Key Metric / Amount | Notes
PBI Incorporated | 2012-03-15 | — | Penterra Biopharma International DAC organized under Irish law
CSA Effective Date / PCT Payment | 2012-07-01 | $312,000,000 | PBI buy-in to pre-existing IP; cost-sharing arrangement commenced
Tax Years Under Examination | 2017–2020 | — | Forms 1120 for TY 2017, 2018, 2019, 2020
Examination Opened (Letter 2205-A) | 2022-05-16 | — | IRS LB&I-NE-TP-2022-00641; Agents Meskill / Dunleavy
C&H Engagement Letter Executed | 2022-06-02 | Est. $4.5M–$7.0M fees | Matter 1018-00009; Cross (Responsible), Hartwell (Billing)
Form 2848 Filed | 2022-06-08 | — | POA for Cross, Hartwell, Simmons, Nazari
Whitmore Kovel Letter Executed | 2022-06-20 | Blended rate $650/hr | Reference 1018-00009-KV; Dr. Vasquez lead economist
IRS Opening Conference | 2022-06-28 | — | Examination scope and focus areas communicated
IDR Period | 2022-06 – 2023-09 | 47 IDRs issued | Comprehensive document production to IRS
NOPA Issued (All Four Years) | 2023-10-12 | $380,400,000 proposed adjustment | CSA: $235.01M; Royalty: $188.04M; Offset: -$42.65M; Proposed penalty: $15.98M
30-Day Letter Issued | 2023-11-08 | — | Deadline to file Protest
Formal Protest Filed | 2023-12-22 | $380,400,000 contested | Transfer pricing defense: CSA ratios, 4.5% royalty, $312M PCT, PBI substance, penalty protection
Case Assigned to Appeals Officer | 2024-01-08 | — | Appeals Officer Noreen Castañeda
Appeals Conference | 2024-02-28 | — | IRS Appeals Office, Manhattan; C&H, PPC, Whitmore presented
Settlement Offer from Appeals | 2024-03-15 | $47,600,000 (12.51% of proposed) | Allocation: $11.2M / $12.4M / $12.8M / $11.2M; penalty fully abated
PPC Accepts Settlement | 2024-03-22 | — | Approved by Iyer (CFO) and Falk (CEO)
Closing Agreement (Form 906) Executed | 2024-03-29 | — | Examination formally closed
Tax Due on Settlement | — | $10,000,000 | $47.6M × 21% = ~$10.0M
Estimated Interest | — | $2,840,000 | At applicable federal underpayment rate
Penalty | — | $0 | Fully abated; reasonable cause / contemporaneous documentation accepted
Total C&H Legal Fees | — | $5,837,420 | Billed through matter close
Total WVG Expert Fees | — | $2,146,800 | Billed through matter close
Total T&K Irish Advisory Fees | — | €312,500 (~$341,200) | At avg. exchange rate ~$1.092/€
Total Professional Fees | — | ~$8,325,420 | C&H + WVG + T&K
Total Cost to PPC | — | ~$21,165,420 | Professional fees + tax + interest
Savings vs. Full Proposed Adjustment | — | $83,020,000 (86.6% reduction) | Proposed tax $79.88M + penalty $15.98M = $95.86M; Actual $12.84M
FIN 48 Reserve (Pre-Settlement) | — | $62,400,000 | ASC 740-10 uncertain tax position reserve
FIN 48 Reserve (Post-Settlement) | — | $14,800,000 | Reduced following $47.6M settlement